You can “lock the gate” for seven days, but you can’t stop

Baytril® 100 (enrofloxacin) Injectable.

Baytril® 100 (enrofloxacin) Injectablefield trial investigates the “lock the gate” BRD treatment regimen.Often, practitioners resort to a “lock the gate” BRD treatment regimen that includes a post-treatment moratorium (PTM). PTM is a variable, 3- to 10-day waiting period following initial BRD treatment and prior to BRD retreatment. Practitioners use a PTM hoping to:

• Avoid treating cattle that do not need retreatment.• Provide sick cattle time to respond to the initial

BRD treatment.• Reduce hospital congestion and costs associated

with retreatment.

Because of the mode of action of some drugs,time-dependent drugs specifically, they need to stay above the MIC (minimum inhibitory concentration) in the animal for several days.

But Baytril 100 is a concentration-dependent drug.Its active ingredient, enrofloxacin, kills bacteria so extended duration of the effective concentration is notnecessary. To confirm this point, Bayer put Baytril 100 and Draxxin® (tulathromycin) to the test in ahead-to-head comparison.1

• 609 Southeastern, high-risk sale barn calves were purchased, commingled and shipped to Nebraska during November.

• Each calf was treated metaphylactically with Micotil® (tilmicosin) at initial processing.

• 199 calves were randomly assigned to study groups as they became ill with BRD.

• 99 calves were allocated to the Draxxin group, 100 calves to the Baytril 100 group.

• The 28-day study utilized a 7-day PTM.• After the 7-day PTM, calves were re-treated for

BRD according to established practices.• Severe winter weather conditions prevailed.

Federal law restricts this drug to use by or on theorder of a licensed veterinarian.

Results — Baytril® 100 proved successful in a PTM treatment regimen.As the following fi gures demonstrate, Baytril 100 performed eff ectively in a BRD treatment regimen utilizing a PTM.

• Though the Draxxin® and Baytril 100 groups had 41 and 49 retreatments, and 20 and 27 second retreatments, respectively, there were no signifi cant statistical diff erences between the two groups.

• 92% of Baytril 100 retreatments occurred in the fi rst seven days following PTM, consolidating retreatment time and labor.

• Draxxin retreatments continued for 18 days following PTM.

Days

PTM

Figure 1. Days to Retreatment1

Num

ber o

f Hea

d

Cattle intended for human consumption must not be slaughtered within 28 days from the last treatment.

• As a further indicator of BRD response, the ADG of the calves was measured. The results of the two groups were comparable, which provides further evidence that Baytril® 100 (enrofl oxacin) Injectable can be used successfully in a 7-day PTM scenario.

By the end of this study, the Baytril 100 grouphad the vast majority of its retreatments in a concise 7-day period. Baytril 100 can be used successfully in a 7-day PTM.

A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to beprocessed for veal.

GroupADG

(Deads in)(lb)

ADG(Deads out)

(lb)

Baytril 100 2.09 2.60

Draxxin 1.12 2.57

Table 1A. Average Daily Gain (ADG)1

Table 1B. Case Fatalities1

Group HeadCase

Fatalities(7-day PTM)

CaseFatalities(All BRD)

Baytril 100 100 1 4

Draxxin 99 3 6

Whether used in a “pull and treat” or “lock the gate” regimen, Baytril® 100 works. In the laboratory,* Baytril 100 kills BRD pathogens in one to two hours,2,3 reducing the population so extended duration of the eff ective concentration is not necessary.

• Baytril 100 is concentration-dependent, reaching therapeutic levels at the site of infections in lungs within 1–2 hours*3 and peak killing concentrationin less than 5 hours in the lungs.*5

• Baytril 100 is bactericidal and kills all four of the majorBRD-causing pathogens.

Despite the fact that Baytril 100 does not remain “on board” for seven days, it’s effective because of its concentration-dependent killing properties. And once bacteria are dead, they’re dead.

Extra-label use of this product in food-producing animals is prohibited.

*The clinical signifi cance of in vitro data has not been demonstrated.

Baytril 100 has a classic concentration-dependent profile.

Hours Post-SubQ Injection

2.0

1.8

1.6

1.4

1.2

1.0

0.8

0.6

0.4

0.2

0

0 2 4 6 8 10 12 14 16 18 20 22 24

MPC 90*3

Drug

Plas

ma C

once

ntra

tion (

μg/m

L)

M. haemolytica

MIC90 = 0.125 μg/mL*4

Pharmacokinetics: 12.5 mg/kg enrofloxacin with active metabolite*3

©2015 Bayer HealthCare LLC, Animal Health, Shawnee Mission, Kansas 66201

Bayer, the Bayer Cross, Baytril and Right the first time are trademarks of Bayer.

Draxxin is a registered trademark of Zoetis.

Micotil is a registered trademark of Eli Lilly and Company.

BL15177

1Data on file.2 Blondeau JM, Borsos S, Blondeau LD, et al. (2005). The killing of clinical isolates of Mannheimia

haemolytica (MH) by enrofloxacin (ENR) using minimum inhibitory and mutant prevention drug

concentrations and over a range of bacterial inocula. In: ASM Conference on Pasteurellaceae;

23-26 October 2005; Kohala Coast, Big Island, Hawaii: American Society of Microbiology; Abstract

B12.3 Blondeau JM, Borsos SD, Hesje CH, et al. (2007). Comparative killing of bovine isolates of

Mannheimia haemolytica (MH) by enrofloxacin, florfenicol, tilmicosin and tulathromycin using the

measured minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC)

drug values. In: International Meeting of Emerging Diseases and Surveillance (IMED); Vienna,

Austria; February 23-25, 2007; Figures 8-10.4Data on file.5 Davis JL, Foster DM, Papich MG. (2007). Pharmacokinetics and tissue distribution of enrofloxacin

and its active metabolite ciprofloxacin in calves. J Vet Pharmacol Ther. 30(6):564-571.